Effects of bismuth therapy on IL-10 and IL-17 in patients with peptic ulcer
10.3760/cma.j.issn.1008-6706.2014.01.004
- VernacularTitle:含铋剂的序贯疗法对消化性溃疡患者血清白细胞介素-10和白细胞介素-17的影响
- Author:
Dongfang CUI
- Publication Type:Journal Article
- Keywords:
Peptic ulcer;
Interlukin-10;
Interlukin-17
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;21(1):8-9
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of containing bismuth sequential therapy on interleukin-10 (IL-10) and interleukin-17 (IL-17) in patients with peptic ulcer.Methods 162 patients with peptic ulcer were randomly divided into two groups,the observation group(n =81 cases) and the control group (n =81 cases).The patients in the observation group were treated through containing bismuth sequential therapy,while the patients in the control group were treated through traditional triple therapy.IL-10 and IL-17 were detected before and after treatment.Results The total effective rates were 97.5% in the observation group and 87.7% in the control group,which of the two groups had significantly difference (x2 =3.96,P ＜ 0.05).Hp eradication rate of the observation group was 96.3 %,and which of the control group was 80.2%,and there was significant difference between the two groups (x2 =4.17,P ＜ 0.05).IL-10 and IL-17 in both groups were significantly decreased after treatment.There was a significant difference between two groups after treatment (t =3.7244,9.3422,all P ＜ 0.05).Conclusion Bismuth-containing sequential therapy can significantly reduce IL-10 and IL-17 in the serum of patients with peptic ulcer.
